2024
Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project
Javanbakht A, Stringer S, Anderson H, Hamilton E, Philip A, Waller E, Langston A, Joseph N, Roback J, Schneider T, Sullivan H, Hendrickson J. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project. Journal Of Clinical Apheresis 2024, 39: e22127. PMID: 38803152, DOI: 10.1002/jca.22127.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzylaminesBlood Component RemovalCyclamsFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansMaleMiddle AgedMultiple MyelomaPeripheral Blood Stem Cell TransplantationPlatelet CountRetrospective StudiesTransplantation, AutologousConceptsStem cell collectionPlatelet countG-CSFMultiple myelomaAutologous peripheral blood stem cell collectionApheresis collectionsPeripheral blood stem cell collectionAutologous stem cell collectionBlood stem cell collectionCell collectionPre-emptive plerixaforBaseline platelet countTransplant doseAutologous collectionApheresisPatientsMedical recordsPlerixaforCollection goalDay of collectionQuality improvement initiativesMyelomaPoor mobilityPlateletCount
2023
Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression
Jajosky R, Patel K, Allen J, Zerra P, Chonat S, Ayona D, Maier C, Morais D, Wu S, Luckey C, Eisenbarth S, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood 2023, 142: 1082-1098. PMID: 37363865, PMCID: PMC10541552, DOI: 10.1182/blood.2022018591.Peer-Reviewed Original ResearchConceptsAntibody-mediated immunosuppressionRBC alloantigensImmune responseFetal red blood cell antigensTarget antigenRed blood cell antigensRh immune globulinMaternal immune responseBlood cell antigensInclusion of antibodiesRBC removalAnti-RhD antibodiesAbility of antibodiesImmune globulinAntibody responseHemolytic diseaseRBC clearanceCell antigensFetal RBCsAntibody characteristicsAlloantigensSimilar interventionsAntibodiesAntigenPolyclonal antibody preparationAssociations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants
DeSimone R, Plimier C, Goel R, Hendrickson J, Josephson C, Patel R, Sola‐Visner M, Roubinian N. Associations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants. Transfusion 2023, 63: 1424-1429. PMID: 37387597, PMCID: PMC10530070, DOI: 10.1111/trf.17468.Peer-Reviewed Original ResearchConceptsLow birth weight infantsRed blood cell transfusionBirth weight infantsBlood cell transfusionVLBW infantsHemoglobin incrementsTransfusion effectivenessCell transfusionWeight infantsRBC transfusionHemoglobin levelsRecipient factorsBlood donorsSingle-unit RBC transfusionsRBC unitsAssociation of donorDonor hemoglobin levelsTransfusion episodesTransfusion eventsClinical outcomesDonor factorsMultivariable regressionTransfusionDonor sexFemale donorsEpidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroids
2022
International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panelEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian ageDonor genetic and non-genetic factors affecting red blood cell transfusion effectiveness
Roubinian NH, Reese SE, Qiao H, Plimier C, Fang F, Page GP, Cable RG, Custer B, Gladwin MT, Goel R, Harris B, Hendrickson JE, Kanias T, Kleinman S, Mast AE, Sloan SR, Spencer BR, Spitalnik SL, Busch MP, Hod EA, . Donor genetic and non-genetic factors affecting red blood cell transfusion effectiveness. JCI Insight 2022, 7: e152598. PMID: 34793330, PMCID: PMC8765041, DOI: 10.1172/jci.insight.152598.Peer-Reviewed Original ResearchConceptsTransfusion effectivenessHemoglobin incrementsRBC transfusionG6PD deficiencyMulticenter retrospective studyRBC storage durationRBC unit transfusionPrecision medicine approachSubset of donorsTransfusion episodesTransfusion requirementsUnit transfusionRecipient factorsRetrospective studyRBC recipientsPatient outcomesRecipient characteristicsChild healthTransfusionVivo hemolysisTransfusion productsMedicine approachNon-genetic factorsOxidative hemolysisSingle nucleotide polymorphisms
2021
Management of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb ATherapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients
Olsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeSmall fiber neuropathyAdverse eventsPlasma exchangeLower extremity paresthesiasSymptomatic response rateAutoantibody-mediated disorderSkin biopsy resultsSFN symptomsTS-HDSExtremity paresthesiasPeripheral neuropathySymptomatic improvementCase seriesIgM antibodiesMean ageTPE proceduresBiopsy resultsTreatment optionsDisease progressionIgM classVasovagal reactionsClose monitoringLaboratory confirmationResponse rateDevelopment of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene
Manrai PA, Siddon AJ, Hager KM, Hendrickson JE, Keller MA, Tormey CA. Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene. Immunohematology 2021, 37: 109-112. PMID: 34591379, DOI: 10.21307/immunohematology-2021-015.Peer-Reviewed Original ResearchConceptsHigh-prevalence antigenReagent red blood cellsDirect antiglobulin testBlood samplesBlood group APatient blood samplesImmunohematology reference laboratoryRare alloantibodyRed blood cellsOncologic careAntiglobulin testGroup APolynesian descentBlood cellsNon-conservative amino acid changeSingle nucleotide variantsReference laboratoryAmino acid changesFamilial backgroundExon 8Antigen expressionExon 7Nucleotide variantsAcid changesExon 4Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola‐Visner M, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Study‐IV‐Pediatric F. Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2021, 61: 2589-2600. PMID: 34455598, DOI: 10.1111/trf.16626.Peer-Reviewed Original ResearchConceptsInternational normalized ratioBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIINational Heart LungTransfusion practicePediatric oncologyRecipient EpidemiologyHSCT patientsPlasma transfusionRed blood cellsPlatelet countHeart LungHematopoietic stem cell transplantation patientsHematopoietic stem cell transplant patientsMedian international normalized ratioStem cell transplant patientsStem cell transplantation patientsLower INR valuesPre-transfusion HbMedian platelet countMulticenter retrospective studyCell transplant patientsCell transplantation patientsStudy IIIAcute myeloid leukemiaEarly but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseThe lysophospholipid‐binding molecule CD1D is not required for the alloimmunization response to fresh or stored RBCs in mice despite RBC storage driving alterations in lysophospholipids
Medved J, Knott BM, Tarrah SN, Li AN, Shah N, Moscovich TC, Boscia AR, Salazar JE, Santhanakrishnan M, Hendrickson JE, Fu X, Zimring JC, Luckey CJ. The lysophospholipid‐binding molecule CD1D is not required for the alloimmunization response to fresh or stored RBCs in mice despite RBC storage driving alterations in lysophospholipids. Transfusion 2021, 61: 2169-2178. PMID: 34181769, PMCID: PMC8856511, DOI: 10.1111/trf.16554.Peer-Reviewed Original ResearchMeSH KeywordsAlarminsAnimalsAntibody SpecificityAntigens, CD1dBlood PreservationBlood TransfusionDuffy Blood-Group SystemErythrocytesFemaleImmunizationImmunoglobulin GImmunoglobulin MIsoantibodiesIsoantigensLysophospholipidsMaleMass SpectrometryMiceMice, Inbred StrainsMice, KnockoutMice, TransgenicMuramidaseOvalbuminReceptors, Cell SurfaceTransfusion ReactionConceptsCD1d-deficient miceCD1d deficiencyRBC alloimmunizationImmune activationNonclassical major histocompatibility complex class IWild-type control miceMajor histocompatibility complex class IHistocompatibility complex class IAdverse clinical consequencesSignificant adverse clinical consequencesLow baseline levelsRBC storageComplex class IHOD RBCsMolecule CD1dRBC transfusionWT miceControl miceImmune responseClinical consequencesMouse modelCD1dCD1d recognitionPolyclonal immunoglobulinsBaseline levelsTransfusion practices in a large cohort of hospitalized children
Nellis ME, Goel R, Hendrickson JE, Birch R, Patel RM, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Sola‐Visner M, Josephson CD, Karam O, Study‐IV‐Pediatric F. Transfusion practices in a large cohort of hospitalized children. Transfusion 2021, 61: 2042-2053. PMID: 33973660, DOI: 10.1111/trf.16443.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood Component TransfusionBlood TransfusionChildChild, PreschoolDatasets as TopicDiagnosis-Related GroupsFemaleHospital MortalityHospitals, CommunityHospitals, TeachingHumansInfantInfant, NewbornInpatientsMaleProcedures and Techniques UtilizationRetrospective StudiesUnited StatesConceptsRBC transfusionCardiopulmonary bypassTransfusion practiceHospitalized childrenInpatient encountersBlood componentsLarge cohortHospital settingBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIIPatient blood management initiativesDiagnostic categoriesFrequency of transfusionInstitutional transfusion guidelinesCohort of patientsInternational normalized ratioPercent of encountersNational Heart LungPediatric hospital settingYears of ageSubset of childrenRecipient EpidemiologyTransfusion guidelinesRed blood cellsEntire cohortMarginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice
Zerra PE, Patel SR, Jajosky RP, Arthur CM, McCoy JW, Allen JWL, Chonat S, Fasano RM, Roback JD, Josephson CD, Hendrickson J, Stowell SR. Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice. Blood 2021, 138: 706-721. PMID: 33876205, PMCID: PMC8394907, DOI: 10.1182/blood.2020009376.Peer-Reviewed Original ResearchConceptsMarginal zone B cellsRBC transfusionMZ B cellsB cellsHOD RBCsAlloantibody formationAntibody responseAntibody formationAntigen-specific germinal center B cellsB cell-deficient recipientsCD4 T-cell depletionRed blood cell transfusionCD4 T cell activationRBC alloantibody formationBlood cell transfusionT-cell depletionCD4 T cellsProbability of complicationsExtrafollicular antibody responsesGerminal center B cellsFollicular B cellsT cell activationRBC alloimmunizationCell transfusionSubsequent transfusionsVariation in Neonatal Transfusion Practice
Patel RM, Hendrickson JE, Nellis ME, Birch R, Goel R, Karam O, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Sola-Visner M, National Heart L, Mast A, Hod E, Custer B, Vichinsky E, Spencer B, Mathew S, Harris D, Busch M, Norris P, Ness P, Kleinman S, Tamburro R, Glynn S, Malkin K. Variation in Neonatal Transfusion Practice. The Journal Of Pediatrics 2021, 235: 92-99.e4. PMID: 33836184, PMCID: PMC8316298, DOI: 10.1016/j.jpeds.2021.04.002.Peer-Reviewed Original ResearchConceptsWeeks of gestationEntire cohortPretransfusion hemoglobinPlatelet countNeonatal transfusionBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIIInternational normalized ratio (INR) valuesHematologic valuesNeonatal transfusion practicesPretransfusion platelet countRetrospective cohort studyBlood product transfusionGestational age groupsPatient blood managementNational Heart LungRecipient EpidemiologyInitial hospitalizationProduct transfusionCohort studyRed blood cellsGestational ageTransfusion practiceHeart LungBlood managementCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agentsOptimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection
Gupta GK, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion And Apheresis Science 2021, 60: 103069. PMID: 33546988, DOI: 10.1016/j.transci.2021.103069.Peer-Reviewed Original ResearchConceptsPeripheral blood CD34Day 1Blood CD34Autologous peripheral blood stem cell collectionAutologous peripheral blood stem cell mobilizationPeripheral blood stem cell mobilizationPeripheral blood stem cell collectionBlood stem cell mobilizationBlood stem cell collectionDose of plerixaforAddition of plerixaforPercent of casesStem cell collectionStem cell mobilizationQuality improvement projectAdult patientsRepeat dosingPeripheral CD34Multiple myelomaCell mobilizationCollection goalGroup 2Retrospective evaluationGroup 1Patient experience
2020
Parasite burden and red blood cell exchange transfusion for babesiosis
O'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. Journal Of Clinical Apheresis 2020, 36: 127-134. PMID: 33179803, PMCID: PMC9517950, DOI: 10.1002/jca.21853.Peer-Reviewed Original ResearchConceptsEnd-organ dysfunctionPeak parasitemia levelsRed blood cell exchange transfusionParasitemia levelsExchange transfusionPeak parasitemiaDisease severityParasite burdenYale-New Haven HospitalBabesia microti parasitemiaHigh-grade parasitemiaRetrospective chart reviewBabesia microti infectionNew Haven HospitalAntimicrobial agentsChart reviewHepatic dysfunctionPatient demographicsClinical statusMedian lengthLaboratory indicatorsMicroti infectionDegree of hemolysisNineteen subjectsDysfunctionPoly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice
Escamilla-Rivera V, Liu J, Gibb DR, Santhanakrishnan M, Liu D, Forsmo JE, Eisenbarth S, Foxman EF, Stowell SR, Luckey CJ, Zimring JC, Hudson KE, Hendrickson J. Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood 2020, 135: 1983-1993. PMID: 32266378, PMCID: PMC7256361, DOI: 10.1182/blood.2020005018.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesCytokinesDisease Models, AnimalErythroblastosis, FetalErythrocyte TransfusionErythrocytesFemaleHumansImmunization, PassiveInterferon Type IIsoantigensKell Blood-Group SystemMembrane GlycoproteinsMetalloendopeptidasesMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicPhagocytosisPoly I-CPregnancyConceptsRed blood cellsSerum monocyte chemoattractant protein-1Monocyte chemoattractant protein-1Blood cellsHuman KEL glycoproteinPolyinosinic-polycytidilic acidTransfused red blood cellsType 1 IFNType I IFN receptorChemoattractant protein-1Type 1 interferonI IFN receptorMurine red blood cellsRecipient CD4Recipient inflammationIFN administrationSerum cytokinesInflammatory monocytesRecipient treatmentInterleukin-6Hemolytic diseaseT cellsMurine modelAlloimmunizationKnockout mice